Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States
Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States
复制标题
DOI：
10.3201/eid2608.191493
复制
发表时间：
2020-08-01
影响因子：
11.8
通讯作者：
Reed, Carrie
中科院分区：
文献类型：
--
作者：
Patel, Manish;Chen, Jufu;Reed, Carrie
越来越多的免疫抑制生物疗法的使用对感染性疾病提出了挑战。免疫抑制的患者患流感并发症的风险很高，对疫苗的免疫反应也会受损。美国免疫抑制疾病的总负担，包括接受新兴生物疗法的患者，仍然未知。我们使用国家索赔数据库MarketScan来估计免疫抑制疾病的患病率和急性呼吸道疾病（阿里斯）的风险。我们研究了4720万名独特的入组者，代表了2012-2017年期间1.15亿人-年的观察，并在6.2%的18-64岁成人和2.6%的儿童中确定了免疫抑制状况
Increasing use of immunosuppressive biologic therapies poses a challenge for infectious diseases. Immunosuppressed patients have a high risk for influenza complications and an impaired immune response to vaccines. The total burden of immunosuppressive conditions in the United States, including those receiving emerging biologic therapies, remains unknown. We used the national claims database MarketScan to estimate the prevalence of immunosuppressive conditions and risk for acute respiratory illnesses (ARIs). We studied 47.2 million unique enrollees, representing 115 million person-years of observation during 2012-2017, and identified immunosuppressive conditions in 6.2% adults 18-64 years of age and 2.6% of children